Gene therapy and ovarian cancer: Update of clinical trials;Therapie genique et cancer de l'ovaire: Expose des essais cliniques en cours

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 29, Issue 6, 2000, Pages 532-537

  Collinet, P ^a   Lanvin, D ^a   Vereecque, R ^a   Quesnel, B ^a   Querleu, D ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Clinical trials; Gene therapy; Ovarian cancer

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 2; MULTIDRUG RESISTANCE PROTEIN; CYTOKINE;

CANCER IMMUNOTHERAPY; CLINICAL TRIAL; FEMALE; GENE THERAPY; GENE TRANSFER; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE NEU; OVARY CANCER; REVIEW; SUICIDE GENE; TUMOR SUPPRESSOR GENE; GENETICS; HORIZONTAL GENE TRANSFER; IMMUNOTHERAPY; MUTATION; OVARY TUMOR;

CLINICAL TRIALS; CYTOKINES; FEMALE; GENE THERAPY; GENE TRANSFER, HORIZONTAL; GENES, BRCA1; GENES, P53; HUMANS; IMMUNOTHERAPY; MUTATION; OVARIAN NEOPLASMS;

EID: 0033742797     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Retroviral vectors
2. Targeted vectors for gene therapy
3. Gene transduction for disseminated intraperitoneal tumor using cationic liposomes containing non-histone chromatin proteins: Cationic liposomal gene therapy of carcinomatosa
4. Tumor suppressor p53 gene: A potential target for cancer therapy?
5. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
6. Advances in the biology of gynecologic cancer
7. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis
8. Role of BRCA1 mutation screening in the management of familial ovarian cancer
9. Ovarian intraepithelial neoplasia and ovarian cancer
10. BRCA1 mutations and survival in women with ovarian cancer
11. Breast cancer genes: Therapeutic strategies
12. Induction of apoptosis by the tumor suppressor protein BRCA1
13. Growth retardation and tumour inhibition by BRCA1
14. BRCA1 protein products: Antibody specificity
15. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta 1 1b
16. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression
17. Mutation analysis of the BRCA1 gene in ovarian cancers
18. A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer
19. The treatment of ovarian cancer with a gene modified cancer vaccine: A phase I study
20. A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV- TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients
21. A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer
22. Human gene marker/therapy clinical protocols
23. Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes
24. A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer
25. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: A pilot trial
26. Gene therapy in the United States: A five-year status report